Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?

Abstract

OPINION STATEMENT:

Management of leiomyosarcoma is based on the specifics of each individual case. Specifically, the location of the disease and whether the disease is metastatic or localized and if localized disease, whether the tumor is resectable or unresectable. In patients with recurrent or metastatic disease, factors such as disease-free interval and pattern of spread should be considered within the context of treatment planning. In general, patients with metastatic disease are typically treated with systemic chemotherapy with either an anthracycline-based regimen or gemcitabine-based regimen as first-line therapy. Additional systemic options include trabectedin, pazopanib, eribulin, and DTIC. Uterine LMS has been the most studied site-specific LMS with respect to systemic therapy. The increasing use of tumor genomics may ultimately define subsets which may benefit from tailored systemic therapies.

• Authors: Jan Philipp Novotny, Suzanne George
• Journal: Current treatment options in oncology (Curr Treat Options Oncol) Vol. 22 Issue 11 Pg. 99 (09 15 2021) ISSN: 1534-6277 [Electronic] United States
• PMID: 34524549 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Topics

• Clinical Decision-Making
• Combined Modality Therapy (adverse effects, methods)
• Disease Management
• Disease Susceptibility
• Humans
• Leiomyosarcoma (diagnosis, etiology, therapy)
• Neoplasm Grading
• Neoplasm Metastasis
• Neoplasm Staging
• Treatment Outcome